Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
Humans
Male
Cisplatin
/ adverse effects
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Antineoplastic Agents
/ adverse effects
Retrospective Studies
Creatinine
/ adverse effects
Uric Acid
/ adverse effects
Carcinoma, Squamous Cell
/ drug therapy
Head and Neck Neoplasms
/ drug therapy
Chemoradiotherapy
/ adverse effects
Acute Kidney Injury
/ chemically induced
Risk Factors
Acute kidney injury
CDDP
Chemoradiation
Cisplatin
Head and neck cancer
Nephrotoxicity
Pre-treatment
Risk factors
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
04
07
2023
revised:
20
09
2023
accepted:
26
09
2023
medline:
23
10
2023
pubmed:
2
10
2023
entrez:
1
10
2023
Statut:
ppublish
Résumé
Cisplatin is essential in the curative treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC) patients. The assessment of risk factors to predict an early cisplatin-induced nephrotoxicity could help in better managing one of the most relevant cisplatin-related dose-limiting factors. We retrospectively collected data of LA-HNSCC patients treated at our Institution from 2008 to 2019. Patients received cisplatin in a curative setting concurrently with radiation. Acute Kidney Injury (AKI) was assessed as a dichotomous variable (CreaIncr) based on pre-treatment values, and values recorded at days 6-20 post-first cycle of cisplatin. Univariable logistic regression models were performed to investigate associations between CreaIncr and clinical characteristics. A multivariable logistic model on a priori selected putative covariates was performed. Of the 350 LA-HNSCC treated patients, 204 were analyzed. Ninety (44 %) suffered from any grade AKI (grade I 51.1 %): out of them, 84.4 % received high-dose cisplatin (100 mg/m2 q21). On the univariable logistic regression model, male sex, age, serum uric acid, creatinine, concomitant drugs, and cisplatin schedule were significantly associated with a higher rate of AKI. At multivariable model, age (p = 0.034), baseline creatinine (p = 0.027), concomitant drugs (p = 0.043), and cisplatin schedule (one-day bolus or fractionated high-dose vs. weekly; p = 0.001) maintained their significant association. Identifying pre-treatment risk factors in LA-HNSCC patients may improve decision-making in a setting where cisplatin has a curative significance. A strict monitoring of AKI could avoid cisplatin dose adjustments, interruptions, and treatment delays, thus limiting a negative impact on outcomes.
Identifiants
pubmed: 37778228
pii: S1368-8375(23)00275-0
doi: 10.1016/j.oraloncology.2023.106579
pii:
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Antineoplastic Agents
0
Creatinine
AYI8EX34EU
Uric Acid
268B43MJ25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106579Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.